Not following ACR practice guidelines potentially leads to unnecessary workups and extra health care costs.
There is significant variability among radiologists’ choice of imaging modality for evaluation of benign and pathologic nipple discharge, according to a study published in the American Journal of Roentgenology.
Researchers from Arizona and Georgia undertook an online survey to assess radiologists' choice of imaging modality for the evaluation of clinical symptoms of physiologic nipple discharge (e.g., bilateral discharge, multiple-duct orifices, and yellow, green, or white color) and pathologic nipple discharge (e.g., unilateral discharge, single-duct orifices, spontaneous and serous discharge, and clear or bloodstained color).
A total of 8,170 surveys were sent to lead interpreting physicians at mammography facilities accredited by the American College of Radiology (ACR). The researchers received 849 responses, for a response rate of 10.4%. For the workup of physiologic nipple discharge, recommendations included:
Practitioners in nonacademic settings and those who read breast images during less than 50% of their practice were significantly more likely to recommend DM (with or without US), compared with SM (the standard recommended by the ACR). Practitioners who read breast images less than 50% of the time were also more likely to recommend MRI after conventional imaging revealed negative results.
Related article: Mammography Focuses on Patient Comfort to Improve Test Rates
For the workup of pathologic nipple discharge, recommendations included:
Nonacademic providers and those who read breast images less than 50% of the time were significantly less likely to recommend DM plus US (the standard recommended by the ACR), compared with DM only.
The researchers concluded that there is variability in imaging modality selection among U.S. radiologists handling the imaging workflow for benign and pathologic nipple discharge. Radiologists do not uniformly follow ACR practice guidelines, which potentially leads to unnecessary workups and extra healthcare costs.
What a New Mammography Study Reveals About BMI, Race, Ethnicity and Advanced Breast Cancer Risk
December 8th 2023In a new study examining population attributable risk proportions (PARPs) based on data from over three million screening mammography exams, researchers found that postmenopausal Black women had the highest BMI-related PARP and premenopausal Asian and Pacific Islander women had the highest breast density-related PARP for advanced breast cancer.
What a New Study Reveals About Adjunctive DBT and Early-Stage Invasive Breast Cancer
December 6th 2023The combination of digital breast tomosynthesis (DBT) and digital mammography had a 21.6 higher invasive breast cancer detection rate for stage 1 tumors than digital mammography alone, according to a new study involving nearly 100,000 women.
GE HealthCare Launches AI Mammography Platform with Key Applications from iCAD
November 30th 2023Offering an all-in-one platform of artificial intelligence (AI) applications, MyBreastAI Suite reportedly facilitates early breast cancer detection and enhances efficiency with breast imaging workflows.